Physician profile
Ashish Patel
NPI 1164873261
$3,733.28
in general payments reported to CMS, 2019-2025
24 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.29 · 2020: $21.27 · 2021: $238 · 2022: $163 · 2023: $593 · 2024: $1,361 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $558.59 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $467.51 | 2021-2024 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $433.07 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $375.37 | 2021-2025 | |
| Pfizer INC. | $365.91 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $277.89 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.74 | 2020-2025 | Jardiance |
| Abbott Laboratories | $130.34 | 2025 | Amplatzer Piccolo |
| Sanofi-Aventis U.S. LLC | $120.33 | 2024-2025 | |
| Glaxosmithkline, LLC. | $119.40 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Alphatec Spine, INC | $114.24 | 2023 | Other - Miscellaneous |
| Axsome Therapeutics, INC. | $104.72 | 2024-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $96.66 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $85.10 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $55.98 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $55.21 | 2019-2024 | Spravato |
| Sumitomo Pharma America, INC. | $52.47 | 2025 | Gemtesa |
| Exact Sciences Corporation | $35.47 | 2023-2025 | Cologuard Collection Kit |
| Agios Pharmaceuticals, INC. | $34.06 | 2025 | Pyrukynd |
| Dynavax Technologies Corporation | $31.84 | 2025 | Heplisav-B |
| Corcept Therapeutics | $27.96 | 2025 | Korlym |
| Nevro Corp. | $25.43 | 2024 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.00 | 2024 | Caplyta |
| Dexcom, INC. | $14.99 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.